These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. MPO-ANCA-associated pulmonary-renal vasculitis in a patient with diabetes mellitus. Keven K; Akar H; Kutlay S; Nergizoglu G; Erbay B; Erturk S J Nephrol; 2002; 15(6):720-3. PubMed ID: 12495292 [TBL] [Abstract][Full Text] [Related]
5. Antineutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis. Mareen P; Van De Walle S; Bernaert P; Vanhouteghem H; Dierick J Acta Clin Belg; 2003; 58(3):193-200. PubMed ID: 12945480 [TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Hu W; Liu C; Xie H; Chen H; Liu Z; Li L Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810 [TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus pneumonitis complicating immunosuppressive treatment for ANCA-positive vasculitis. Jones R; Shah S; MacMahon EE; Goldsmith DJ Nephrol Dial Transplant; 2003 Sep; 18(9):1920-2. PubMed ID: 12937244 [No Abstract] [Full Text] [Related]
10. Evidence-based management of ANCA vasculitis. Carruthers D; Sherlock J Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):367-78. PubMed ID: 19508944 [TBL] [Abstract][Full Text] [Related]
11. Recurrent drug-induced ANCA vasculitis in a patient with Crohn's colitis treated with infliximab: a potential contraindication to immunosuppressive therapy. Rosen DR; Cologne KG; Popek SM; Sung BC; Ortega AE; Senagore AJ Am Surg; 2012 Dec; 78(12):1406-8. PubMed ID: 23265134 [No Abstract] [Full Text] [Related]
12. Adverse effects of therapy for ANCA-associated vasculitis. Turnbull J; Harper L Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):391-401. PubMed ID: 19508946 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effect and clinical findings in patients with MPO-ANCA associated vasculitis syndrome]. Yoshida A; Takeda A; Fukuda M; Toda S; Morozumi K Ryumachi; 2000 Feb; 40(1):1-8. PubMed ID: 10783659 [TBL] [Abstract][Full Text] [Related]
14. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. de Lind van Wijngaarden RA; Hauer HA; Wolterbeek R; Jayne DR; Gaskin G; Rasmussen N; Noël LH; Ferrario F; Waldherr R; Hagen EC; Bruijn JA; Bajema IM J Am Soc Nephrol; 2006 Aug; 17(8):2264-74. PubMed ID: 16825335 [TBL] [Abstract][Full Text] [Related]
15. Treatment of ANCA-associated systemic vasculitis. Belmont HM Bull NYU Hosp Jt Dis; 2006; 64(1-2):60-6. PubMed ID: 17121492 [TBL] [Abstract][Full Text] [Related]
17. Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: a single-center experience. Stangou M; Asimaki A; Bamichas G; Christidou F; Zoumbaridis N; Natse T; Galanis N; Christaki P; Patakas D; Sombolos K J Nephrol; 2005; 18(1):35-44. PubMed ID: 15772921 [TBL] [Abstract][Full Text] [Related]
18. Part 1: The need for novel treatment regimens for ANCA-associated vasculitis. Merkel PA Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S72-3. PubMed ID: 17428375 [No Abstract] [Full Text] [Related]
19. When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy? Flossmann O; de Groot K Nat Clin Pract Nephrol; 2007 May; 3(5):236-7. PubMed ID: 17457358 [No Abstract] [Full Text] [Related]
20. [Diagnosis und therapy of ANCA-associated vasculitis]. Aries PM; Hellmich B; Gross WL Dtsch Med Wochenschr; 2006 Mar; 131(9):443-6. PubMed ID: 16493569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]